stockportfolio.pro
Stocks / PCRX vs SPRY
PCRX vs SPRY
Pacira BioSciences, Inc. and ARS Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Pacira BioSciences, Inc. (PCRX) | ARS Pharmaceuticals, Inc. (SPRY) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $726.41M | $84.28M |
| Net income (latest FY) | $7.03M | $-171.30M |
| Revenue growth (5y CAGR) | 11.1% | — |
| Net margin | 1.0% | -203.3% |
| Return on equity | 1.0% | -149.9% |
| P/E ratio | 180.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PCRX — free Open SPRY — freeFrequently asked questions
Which is bigger, PCRX or SPRY?
ARS Pharmaceuticals, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, PCRX or SPRY?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.